U

Universitatsklinikum Essen | Ruhrlandklinik - Zentrum fur Schlaf- und Telemedizin

Research site
(Unclaimed)
Location
Tüschener Weg 40, Essen, North Rhine-Westphalia, Germany

Site insights

Top conditions

Top treatments

Daratumumab
Apalutamide
INCMGA00012
JNJ-73763989
Azacitidine
Ustekinumab
Palbociclib
Ivosidenib
Dexamethasone
Risdiplam

Parent organization

This site is a part of Universitatsklinikum Essen

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 22 total trials

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Enrolling
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectom...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Apalutamide

The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimen...

Enrolling
Amyloidosis
Drug: Cyclophosphamide
Drug: Dexamethasone

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma...

Active, not recruiting
Metastatic Merkel Cell Carcinoma
Drug: Retifanlimab

The purpose of the study is to evaluate on-treatment efficacy against hepatitis D virus (HDV) of JNJ-73763989 + nucleos(t)ide analog (NA) regimen com...

Active, not recruiting
Hepatitis D, Chronic
Drug: Tenofovir alafenamide (TAF)
Drug: JNJ-73763989

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Enrolling
Bladder Cancer
Biological: Cetrelimab
Biological: BCG Vesiculture

The purpose of this study is to evaluate the efficacy of ustekinumab dosing in inducing clinical remission (Global) and in maintaining clinical remis...

Active, not recruiting
Crohn Disease
Drug: Ustekinumab
Drug: Placebo

The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and...

Active, not recruiting
Colitis, Ulcerative
Drug: Matching Placebo
Drug: Ustekinumab Dose Based on BSA and Body Weight

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared...

Active, not recruiting
Amyloidosis
Drug: Cyclophosphamide
Drug: Daratumumab

The primary objective of the study is to evaluate the safety and tolerability of single ascending dose of BIIB115 administered via intrathecal (IT) b...

Enrolling
Muscular Atrophy, Spinal
Healthy Volunteer
Drug: BIIB115
Drug: BIIB115-Matching Placebo

This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at...

Enrolling
Muscular Atrophy, Spinal
Drug: Risdiplam

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Enrolling
Warm Autoimmune Hemolytic Anemia
Drug: M281
Drug: Placebo

The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Ty...

Active, not recruiting
Anti-myostatin
Neuromuscular Manifestations
Drug: Apitegromab

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients wi...

Active, not recruiting
Membranoproliferative Glomerulonephritis (MPGN)
Membranoproliferative Glomerulonephritis
Other: Placebo
Drug: Pegcetacoplan

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic...

Active, not recruiting
Metastatic Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Drug: Cemiplimab
Biological: RP1

The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, an...

Enrolling
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two...

Active, not recruiting
Duchenne Muscular Dystrophy
Genetic: PF-06939926
Other: Placebo

Trial sponsors

J
Incyte logo
Pfizer logo
A
BeiGene logo
Biogen logo
Gilead Sciences logo
J
R
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems